Skip to content

Study · Not a test of the peptide alone · 2008

6 results

Prevention of developmental delays in a Down syndrome mouse model.

Toso L, Cameroni I, Roberson R, Abebe D, Bissell S, Spong CY

Obstetrics and gynecology1 Dec 2008Cited by 38 (Europe PMC)

PMID19037032 (opens in a new tab)PMCIDPMC2687469 (opens in a new tab)DOI10.1097/aog.0b013e31818c91dc (opens in a new tab)PepBankPUB-19037032
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Davunetide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Davunetide.

  1. 01AnimalNot a test of Davunetide aloneAnimal study (in vivo)Efficacy outcome

    In trisomic mice, prenatal NAPVSIPQ+SALLRSIPA produced control timing for three of four motor milestones.

    In plain wordsIn trisomic mice, the NAPVSIPQ+SALLRSIPA combination produced the same timing as controls for three of four motor milestones.

    Peptide
    Davunetide
    Outcome
    Direction not reportedMotor developmental milestones
    Study

    Mousen: not reported in source

    Ts65Dn offspring
    Comparator
    Controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Trisomic mice that were prenatally exposed to NAPVSIPQ+SALLRSIPA achieved developmental milestones at the same time as the controls in three of four motor and one of four sensory milestones (P<.01).
    2 context sentences
    Summary · context
    Pregnant Ts65Dn females were randomly assigned to NAPVSIPQ+SALLRSIPA or control and were treated by investigators blinded to treatment and genotype on gestational days 8-12.
    Summary · context
    Offspring were tested from postnatal day 5 to 21 for motor and sensory milestones with standardized tests by operators blinded to the pup's treatment and genotype.

    In this study, Davunetide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Davunetide.

  2. 02AnimalNot a test of Davunetide aloneAnimal study (in vivo)Efficacy outcome

    In trisomic mice, prenatal NAPVSIPQ+SALLRSIPA produced control timing for one of four sensory milestones.

    In plain wordsIn trisomic mice, the NAPVSIPQ+SALLRSIPA combination produced the same timing as controls for one of four sensory milestones.

    Peptide
    Davunetide
    Outcome
    Direction not reportedSensory developmental milestones
    Study

    Mousen: not reported in source

    Ts65Dn offspring
    Comparator
    Controls
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Trisomic mice that were prenatally exposed to NAPVSIPQ+SALLRSIPA achieved developmental milestones at the same time as the controls in three of four motor and one of four sensory milestones (P<.01).
    2 context sentences
    Summary · context
    Pregnant Ts65Dn females were randomly assigned to NAPVSIPQ+SALLRSIPA or control and were treated by investigators blinded to treatment and genotype on gestational days 8-12.
    Summary · context
    Offspring were tested from postnatal day 5 to 21 for motor and sensory milestones with standardized tests by operators blinded to the pup's treatment and genotype.

    In this study, Davunetide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Davunetide.

  3. 03AnimalNot a test of Davunetide aloneAnimal study (in vivo)Efficacy outcome

    In euploid mice, prenatal NAPVSIPQ+SALLRSIPA advanced developmental milestones significantly compared with prenatal placebo.

    In plain wordsIn euploid mice, the NAPVSIPQ+SALLRSIPA combination produced earlier developmental milestones than placebo.

    Peptide
    Davunetide
    Outcome
    DecreaseDevelopmental milestone timing
    Study

    Mousen: not reported in source

    Euploid offspring
    Comparator
    Prenatal placebo
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Euploid pups prenatally treated with NAPVSIPQ+SALLRSIPA achieved developmental milestones significantly earlier than the euploid pups prenatally treated with placebo.
    2 context sentences
    Summary · context
    Pregnant Ts65Dn females were randomly assigned to NAPVSIPQ+SALLRSIPA or control and were treated by investigators blinded to treatment and genotype on gestational days 8-12.
    Summary · context
    Offspring were tested from postnatal day 5 to 21 for motor and sensory milestones with standardized tests by operators blinded to the pup's treatment and genotype.

    In this study, Davunetide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Davunetide.

  4. 04AnimalNot a test of Davunetide aloneAnimal study (in vivo)Mechanism

    In Ts65Dn brains, prenatal NAPVSIPQ+SALLRSIPA prevented activity-dependent neurotrophic factor downregulation, with expression not different from controls.

    In plain wordsIn trisomic mice, the NAPVSIPQ+SALLRSIPA combination prevented loss of neurotrophic factor expression, with levels not different from controls.

    Peptide
    Davunetide
    Outcome
    IncreaseActivity-dependent neurotrophic factor expression
    Study

    Mousen: not reported in source

    Ts65Dn brains
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    Activity-dependent neurotrophic factor expression was significantly downregulated in the Ts65Dn brains compared with the controls, prenatal treatment with NAPVSIPQ+ SALLRSIPA prevented the activity-dependent neurotrophic factor decrease in the Ts65Dn brains, and the expression was not different from the controls.
    2 context sentences
    Summary · context
    Pregnant Ts65Dn females were randomly assigned to NAPVSIPQ+SALLRSIPA or control and were treated by investigators blinded to treatment and genotype on gestational days 8-12.
    Summary · context
    Offspring were tested from postnatal day 5 to 21 for motor and sensory milestones with standardized tests by operators blinded to the pup's treatment and genotype.

    In this study, Davunetide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Davunetide.

  5. 05AnimalNot a test of Davunetide aloneAnimal study (in vivo)Mechanism

    In Ts65Dn mice, NAPVSIPQ+SALLRSIPA prevented downregulation of glial fibrillary acidic protein.

    In plain wordsIn trisomic mice, the NAPVSIPQ+SALLRSIPA combination prevented reduced expression of a glial marker.

    Peptide
    Davunetide
    Outcome
    IncreaseGlial fibrillary acidic protein expression
    Study

    Mousen: not reported in source

    Ts65Dn brains
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    The glial marker glial fibrillary acidic protein demonstrated the known glial deficit in the Ts65Dn mice, and treatment with NAPVSIPQ+ SALLRSIPA prevented its downregulation.
    2 context sentences
    Summary · context
    Pregnant Ts65Dn females were randomly assigned to NAPVSIPQ+SALLRSIPA or control and were treated by investigators blinded to treatment and genotype on gestational days 8-12.
    Summary · context
    Offspring were tested from postnatal day 5 to 21 for motor and sensory milestones with standardized tests by operators blinded to the pup's treatment and genotype.

    In this study, Davunetide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Davunetide.

  6. 06AnimalNot a test of Davunetide aloneAnimal study (in vivo)Mechanism

    In trisomic mouse brains, NAPVSIPQ+SALLRSIPA did not prevent vasoactive intestinal peptide upregulation.

    In plain wordsIn trisomic mice, the NAPVSIPQ+SALLRSIPA combination did not prevent increased vasoactive intestinal peptide levels.

    Peptide
    Davunetide
    Outcome
    Not applicableVasoactive intestinal peptide upregulation
    Study

    Mousen: not reported in source

    Ts65Dn brains
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    Lastly, vasoactive intestinal peptide levels were increased in the trisomic brains, whereas treatment with NAPVSIPQ+SALLRSIPA did not prevent its upregulation.
    2 context sentences
    Summary · context
    Pregnant Ts65Dn females were randomly assigned to NAPVSIPQ+SALLRSIPA or control and were treated by investigators blinded to treatment and genotype on gestational days 8-12.
    Summary · context
    Offspring were tested from postnatal day 5 to 21 for motor and sensory milestones with standardized tests by operators blinded to the pup's treatment and genotype.

    In this study, Davunetide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Davunetide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.